Epidemiology of XXXX . A community-based study in urban and rural populations in the state of Nuevo Leon, Mexico.

@entity1 @entity4512 @entity239 @entity627 @entity571 @entity625 @entity158 @entity309 @entity130
OBJECTIVE: To estimate the prevalence of @entity627 in rural and urban populations using the WHO-ILAR COPCORD questionnaire. METHODS: We conducted a cross-sectional home survey in subjects > 18 years of age in the Mexican state of Nuevo Leon. Results were validated locally against physical examination in positive cases according to an operational definition by 2 rheumatologists. We used a random, balanced, and stratified sample by region of representative subjects. RESULTS: We surveyed 4713 individuals with a mean age of 43.6 years (SD 17.3); 55.9% were @entity1 and 87.1% were from urban areas. Excluding @entity130 , 1278 individuals (27.1%, 95% CI 25.8%-28.4%) reported @entity4512 in the last 7 days; the prevalence of this variable was almost twice as frequent in @entity1 (33% vs 17% in @entity1 ); 529 (11.2%) had @entity158 associated with @entity130 . The global prevalence of @entity158 was 38.3%. Mean @entity158 score was 2.4 (SD 3.4) on a @entity158 scale of 0-10. Most subjects classified as positive according to case definition (99%) were evaluated by a rheumatologist. Main diagnoses were @entity571 in 17.3% (95% CI 16.2-18.4), back @entity158 in 9.8% (95% CI 9.0-10.7), undifferentiated @entity625 in 2.4% (95% CI 2.0-2.9), @entity309 in 0.4% (95% CI 0.2-0.6), @entity239 in 0.8% (95% CI 0.6-1.1), and gout in 0.3% (95% CI 0.1-0.5). CONCLUSION: This is the first regional COPCORD study in Mexico performed with a systematic sampling, showing a high prevalence of @entity158 . COPCORD is a useful tool for the early detection of @entity627 as well as for accurately referring @entity1 to different medical care centers and to reduce underreporting of @entity627 .
